{
  "docId": "019de075-c130-77ea-b60f-b21955e0fc8e",
  "docSlug": "71c1598fd07d494c4a73d86584bdcfa9",
  "documentTitle": "Nuvalent | Investor Presentation Deck | 39 slides",
  "authorId": "nuvalent",
  "authorName": "Nuvalent",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 39,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "competitive_analysis",
  "function": "compare_peers",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The table uses a green/white color coding to highlight positive attributes of NVL-655 compared to competitors.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de075-c130-77ea-b60f-b21955e0fc8e/29",
  "deckHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e",
  "deckJsonHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e.json",
  "deckAnchorHref": "/decks/019de075-c130-77ea-b60f-b21955e0fc8e#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.06,
        "w": 0.85,
        "x": 0.077,
        "y": 0.845
      },
      "kind": "disclaimer",
      "text": "No head-to-head clinical studies have been conducted for currently approved or investigational therapies versus NVL-655. Clinical investigation of NVL-655 is ongoing.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "87d3b3a2-9e27-4e00-8a1c-c254e1659ca2",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.55,
        "w": 0.85,
        "x": 0.075,
        "y": 0.265
      },
      "kind": "table",
      "text": "Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "53fb4dcd-a982-40da-9aff-af788a0af1dc",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.45,
        "x": 0.077,
        "y": 0.188
      },
      "kind": "title",
      "text": "Differentiated Product Candidate for ALK-positive NSCLC patients",
      "attrs": null,
      "subkind": "action-title",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "941b5935-6587-4679-9478-a1fdc3eee9d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.055,
        "w": 0.145,
        "x": 0.077,
        "y": 0.115
      },
      "kind": "title",
      "text": "NVL-655",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "808649e2-8790-4780-98a3-a13e627f8772",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "NxN matrix",
      "slug": "matrix-nxn",
      "agent": null,
      "layer": "slide",
      "matchId": "c8a6a78f-3a24-448c-8530-e748747e6e8c",
      "evidence": "table/data: Comparison matrix of NVL-655 vs Crizotinib, Ceritinib, Alectinib, Brigatinib, Lorlatinib across 5 activity categories",
      "confidence": 0.7
    }
  ],
  "frameworks": [
    {
      "name": "comparison-frame",
      "slug": null,
      "matchId": "f0c8731e-a666-42e2-b4f6-eca59f65b937",
      "evidence": "Table comparing product features against competitors",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}